Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

Thymoma and Thymic Carcinoma Clinical Trial

Official title:
Hypofractionated Radiotherapy Combined With Concurrent Weekly Chemotherapy and Thymosin α1 in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-arm Phase II Study

Status Active, not recruiting

Clinical Trial Summary

This phase II study was to assess the efficacy and toxicity of hypofractionated radiotherapy (HRT) combined with weekly docetaxel/platinum and thymosin α1 in patients with unresectable or recurrent thymic epithelia tumors (TETs).

Clinical Trial Description

HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used. All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy . Meanwhile they received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03663764
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 13, 2018
Completion date	August 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00003283` - Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma	Phase 2
Completed	`NCT00372840` - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer	N/A
Completed	`NCT00024076` - Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer	Phase 2
Completed	`NCT02636556` - Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors	N/A
Completed	`NCT02049047` - Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy	Phase 2
Recruiting	`NCT02633514` - Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma	Phase 3
Recruiting	`NCT04554524` - Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma	Phase 4
Recruiting	`NCT06301945` - Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors